Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)

NCT03008278 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03008278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03008278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Completed
Start date
February 6, 2018
Completion date
August 13, 2025
Enrollment
51 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic esophageal carcinoma, metastatic gastric carcinoma, metastatic gastroesophageal junction adenocarcinoma, recurrent esophageal carcinoma, recurrent gastric carcinoma, recurrent gastroesophageal junction adenocarcinoma, stage iii esophageal cancer ajcc v7, stage iii gastric cancer ajcc v7, stage iv esophageal cancer ajcc v7, stage iv gastric cancer ajcc v7, unresectable esophageal carcinoma, unresectable gastric carcinoma, unresectable gastroesophageal junction adenocarcinoma